U.S. Markets close in 1 hr 33 mins

Will Endocyte (ECYT) Crush Estimates at Its Next Earnings Report?

Zacks Equity Research

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Endocyte, Inc. (ECYT), a firm in the Medical Drugs industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ECYT has beaten estimates by at least 35% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, ECYT expected to incur a loss of 13 cents per share, while it actually incurred a loss of 8 cents per share, a beat of 38.5%. Meanwhile, for the most recent quarter, the company looked to report loss of 15 cents per share, when it actually saw loss of 9 cents per share instead, representing a 40.0% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for Endocyte. In fact, the Earnings ESP for ECYT is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ECYT, as the firm currently has a positive Zacks Earnings ESP, so another beat could be around the corner.

This is particularly true when you consider that ECYT has a great Zacks Rank #1 (Strong Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ECYT could see another beat at its next report, especially if recent trends are any guide.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

ENDOCYTE INC (ECYT): Free Stock Analysis Report

Zacks Investment Research